The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Peripheral Blood Stem Cell Transplantation

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Peripheral Blood Stem Cell Transplantation


Psychiatry related information on Peripheral Blood Stem Cell Transplantation


High impact information on Peripheral Blood Stem Cell Transplantation


Chemical compound and disease context of Peripheral Blood Stem Cell Transplantation


Biological context of Peripheral Blood Stem Cell Transplantation


Anatomical context of Peripheral Blood Stem Cell Transplantation


Associations of Peripheral Blood Stem Cell Transplantation with chemical compounds


Gene context of Peripheral Blood Stem Cell Transplantation


Analytical, diagnostic and therapeutic context of Peripheral Blood Stem Cell Transplantation


  1. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Advani, R., Chao, N.J., Horning, S.J., Blume, K.G., Ahn, D.K., Lamborn, K.R., Fleming, N.C., Bonnem, E.M., Greenberg, P.L. Ann. Intern. Med. (1992) [Pubmed]
  2. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Gyger, M., Sahovic, E., Aslam, M. Blood (1998) [Pubmed]
  3. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Kessinger, A., Bierman, P.J., Vose, J.M., Armitage, J.O. Blood (1991) [Pubmed]
  4. Persistent Mycobacterium avium infection following nonmyeloablative allogeneic peripheral blood stem cell transplantation for interferon-gamma receptor-1 deficiency. Horwitz, M.E., Uzel, G., Linton, G.F., Miller, J.A., Brown, M.R., Malech, H.L., Holland, S.M. Blood (2003) [Pubmed]
  5. Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way. Mehta, J., Singhal, S. J. Clin. Oncol. (2002) [Pubmed]
  6. Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study. Schey, S., Ahsan, G., Jones, R. Bone Marrow Transplant. (1999) [Pubmed]
  7. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Nakamae, H., Tsumura, K., Hino, M., Hayashi, T., Tatsumi, N. Lancet (2000) [Pubmed]
  8. In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation. Voermans, C., Kooi, M.L., Rodenhuis, S., van der Lelie, H., van der Schoot, C.E., Gerritsen, W.R. Blood (2001) [Pubmed]
  9. Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children? Ojeda, E., Garcia-Bustos, J., Agaudo, M.J., Quevedo, E., Arrieta, R., Jimenez, V., Canales, M., Hernandez-Navarro, F. Blood (1999) [Pubmed]
  10. BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties. Hunter, M.G., Bawden, L., Brotherton, D., Craig, S., Cribbes, S., Czaplewski, L.G., Dexter, T.M., Drummond, A.H., Gearing, A.H., Heyworth, C.M., Lord, B.I., McCourt, M., Varley, P.G., Wood, L.M., Edwards, R.M., Lewis, P.J. Blood (1995) [Pubmed]
  11. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. Dispenzieri, A., Lacy, M.Q., Kyle, R.A., Therneau, T.M., Larson, D.R., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A., Gertz, M.A. J. Clin. Oncol. (2001) [Pubmed]
  12. Induction of autologous graft-versus-host disease with cyclosporin A after peripheral blood stem cell transplantation: analysis of factors affecting induction. Miura, Y., Ueda, M., Zeng, W., Wang, H., Takami, A., Yamazaki, H., Kawamura, Y., Shiobara, S., Nakao, S. J. Allergy Clin. Immunol. (2000) [Pubmed]
  13. Induction of autologous graft-versus-host disease after autologous peripheral blood stem cell transplantation. Nakamura, H., Nakao, T., Ujiie, H., Karasuno, T., Teshima, H., Komatsu, K., Ishiguro, S., Hiraoka, A., Masaoka, T. J. Allergy Clin. Immunol. (1999) [Pubmed]
  14. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Scheulen, M.E., Hilger, R.A., Oberhoff, C., Casper, J., Freund, M., Josten, K.M., Bornhäuser, M., Ehninger, G., Berdel, W.E., Baumgart, J., Harstrick, A., Bojko, P., Wolf, H.H., Schindler, A.E., Seeber, S. Clin. Cancer Res. (2000) [Pubmed]
  15. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Casserly, L.F., Fadia, A., Sanchorawala, V., Seldin, D.C., Wright, D.G., Skinner, M., Dember, L.M. Kidney Int. (2003) [Pubmed]
  16. Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Fischer, T., Reifenrath, C., Hess, G.R., Corsetti, M.T., Kreil, S., Beck, J., Meinhardt, P., Beltrami, G., Schuch, B., Gschaidmeier, H., Hehlmann, R., Hochhaus, A., Carella, A., Huber, C. Leukemia (2002) [Pubmed]
  17. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Valcárcel, D., Martino, R., Caballero, D., Mateos, M.V., Pérez-Simón, J.A., Canals, C., Fernández, F., Bargay, J., Muñiz-Díaz, E., Gonzalez, M., San Miguel, J.F., Sierra, J. Bone Marrow Transplant. (2003) [Pubmed]
  18. Early establishment of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation in comparison with allogeneic bone marrow transplantation. Nakao, S., Zeng, W., Yamazaki, H., Wang, H., Takami, A., Sugimori, N., Miura, Y., Shiobara, S., Matsuda, T., Shinagawa, Y., Harada, M. Eur. J. Haematol. (1999) [Pubmed]
  19. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures. Karussis, D., Slavin, S. J. Neurol. Sci. (2004) [Pubmed]
  20. Transient improvement of left ventricular function after peripheral blood stem cell transplantation in a patient with myelodysplastic syndrome and dilated cardiomyopathy. Ogawa, K., Yaoita, H., Okamoto, M., Ikeda, K., Shichishima, T., Ohto, H., Maehara, K., Maruyama, Y. Circ. J. (2004) [Pubmed]
  21. T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Baron, F., Schaaf-Lafontaine, N., Humblet-Baron, S., Meuris, N., Castermans, E., Baudoux, E., Frère, P., Bours, V., Fillet, G., Beguin, Y. Transplantation (2003) [Pubmed]
  22. Immune reconstitution and production of intracellular cytokines in T lymphocyte populations following autologous peripheral blood stem cell transplantation. Schlenke, P., Sheikhzadeh, S., Weber, K., Wagner, T., Kirchner, H. Bone Marrow Transplant. (2001) [Pubmed]
  23. Angina pectoris occurring during granulocyte colony-stimulating factor-combined preparatory regimen for autologous peripheral blood stem cell transplantation in a patient with acute myelogenous leukaemia. Fukumoto, Y., Miyamoto, T., Okamura, T., Gondo, H., Iwasaki, H., Horiuchi, T., Yoshizawa, S., Inaba, S., Harada, M., Niho, Y. Br. J. Haematol. (1997) [Pubmed]
  24. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. Ballester, O.F., Agaliotis, D.P., Hiemenz, J.W., Janssen, W.E., Fields, K.K., Zorksy, P.E., Goldstein, S.C., Perkins, J.B., Elfenbein, G.J. Bone Marrow Transplant. (1996) [Pubmed]
  25. Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. Baron, F., Frère, P., Fillet, G., Beguin, Y. Br. J. Haematol. (2003) [Pubmed]
  26. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Hiemenz, J., Cagnoni, P., Simpson, D., Devine, S., Chao, N., Keirns, J., Lau, W., Facklam, D., Buell, D. Antimicrob. Agents Chemother. (2005) [Pubmed]
  27. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia. Schlenk, R.F., Hartmann, F., Hensel, M., Jung, W., Weber-Nordt, R., Gabler, A., Haas, R., Ho, A.D., Trümper, L., Döhner, H. Leukemia (2002) [Pubmed]
  28. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. Fetscher, S., Brugger, W., Engelhardt, R., Kanz, L., Hasse, J., Frommhold, H., Lange, W., Mertelsmann, R. Ann. Oncol. (1999) [Pubmed]
  29. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma. Salar, A., Martino, R., Perea, G., Ribera, J.M., López-Guillermo, A., Guardia, R., Escoda, L., Altés, A., Sierra, J., Montserrat, E. Haematologica (2002) [Pubmed]
  30. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Tosi, P., Ronconi, S., Zamagni, E., Cellini, C., Grafone, T., Cangini, D., Pileri, S.A., Baccarani, M., Tura, S., Cavo, M. Haematologica (2001) [Pubmed]
  31. Prolonged molecular remission after PML/RAR alpha-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft? Sanz, M.A., de la Rubia, J., Bonanad, S., Barragán, E., Sempere, A., Martín, G., Martínez, J.A., Jiménez, C., Cervera, J., Bolufer, P., Sanz, G.F. Leukemia (1998) [Pubmed]
  32. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Eder, M., Battmer, K., Kafert, S., Stucki, A., Ganser, A., Hertenstein, B. Leukemia (1999) [Pubmed]
  33. TNFalpha, interleukin-10 and interleukin-18 expression in cells of the bronchoalveolar lavage in patients with pulmonary complications following bone marrow or peripheral stem cell transplantation: a preliminary study. Hauber, H.P., Mikkilä, A., Erich, J.M., Kröger, N., Meyer, A., Schoder, V., Zander, A.R., Pforte, A. Bone Marrow Transplant. (2002) [Pubmed]
  34. Human hematopoietic growth factors: old lessons and new perspectives. Dempke, W., Von Poblozki, A., Grothey, A., Schmoll, H.J. Anticancer Res. (2000) [Pubmed]
  35. In vitro expansion of CD34+/CD41+ cells from human peripheral blood CD34+/CD41- cells: role of cytokines for in vitro proliferation and differentiation of megakaryocytic progenitors. Koizumi, K., Sawada, K., Yamaguchi, M., Notoya, A., Tarumi, T., Takano, H., Fukada, Y., Nishio, M., Katagiri, E., Yasukouchi, T., Sato, N., Sekiguchi, S., Koike, T. Exp. Hematol. (1998) [Pubmed]
  36. Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis. Nieboer, P., de Vries, E.G., Vellenga, E., van der Graaf, W.T., Mulder, N.H., Sluiter, W.J., de Wolf, J.T. Eur. J. Cancer (2004) [Pubmed]
  37. CD34(+) cell subsets and long-term culture colony-forming cells evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients undergoing autologous peripheral blood stem cell transplantation. Lanza, F., Campioni, D., Moretti, S., Dominici, M., Punturieri, M., Focarile, E., Pauli, S., Dabusti, M., Tieghi, A., Bacilieri, M., Scapoli, C., De Angeli, C., Galluccio, L., Castoldi, G. Exp. Hematol. (2001) [Pubmed]
  38. Busulfan clearance in renal failure and hemodialysis. Ullery, L.L., Gibbs, J.P., Ames, G.W., Senecal, F.M., Slattery, J.T. Bone Marrow Transplant. (2000) [Pubmed]
  39. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Kim, H., Sohn, H.J., Kim, S.E., Kang, H.J., Park, S., Kim, S., Kim, W.K., Lee, J.S., Suh, C. Bone Marrow Transplant. (2004) [Pubmed]
  40. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Neubauer, M.A., Benyunes, M.C., Thompson, J.A., Bensinger, W.I., Lindgren, C.G., Buckner, C.D., Fefer, A. Bone Marrow Transplant. (1994) [Pubmed]
WikiGenes - Universities